


July 13, 2020



Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®

NEW YORK, July 13, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "RLMD."



The Nasdaq Global Select Market® is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Investor Contact:

Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com

For Media Inquiries:

FischTank PR
relmada@fischtankpr.com

 View original content to download multimedia <http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-uplisting-to-the-nasdaq-global-select-market-301092149.html>

SOURCE Relmada Therapeutics, Inc.